Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 8, 2021 4:05 PM ESTFinancial Highlights, 2021 Revenue Guidance and Legal Update
Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 20192021 revenue guidance $375 - 405 millionPreliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share in fourth quarter 2019Preliminary cash and investments at December 31, 2020 of $476.9 million, an increase of $161.6 million from December 31, 2019Patent Trial and Appeals Board... More